Will Fate Therapeutics stock go up?

According to Danelfin AI, Fate Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Fate Therapeutics stock?

The Fate Therapeutics target price is $7.83 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Fate Therapeutics stock right now?

Fate Therapeutics has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Fate Therapeutics stock is a good buy .

Is Fate Therapeutics undervalued right now?

Based on analysts, the average price target upside for Fate Therapeutics is +157.62% (1Y). According to Danelfin AI, Fate Therapeutics has today an AI Score of 5/10 (Hold Rating).

What was the price range of Fate Therapeutics stock over the past 12 months?

The Fate Therapeutics stock price range over the past 12 months has been $0.92 - $3.04.

What is going on with Fate Therapeutics stock in the last 3 months?

The Fate Therapeutics stock performance in the last quarter has been +153.33%.

Does Fate Therapeutics offer dividend payments?

No, Fate Therapeutics does not currently pay dividends.

What is the current market capitalization of Fate Therapeutics?

Fate Therapeutics's market cap is $352.01M, as of 2026-07-02 08:00.

When is the next FATE earnings report date?

FATE will publish its next earnings report on 2026-05-13.

Fate Therapeutics Inc (FATE) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

FATE AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Fate Therapeutics Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 53% probability of outperforming the market in the next 3 months, which is 2% higher than the average probability of any stock (51%). Key positive contributors include the long tail of fundamentals (impact +2.38%), the Biotechnology industry (+1.31%), and the 60-day chart pattern (+0.37%). On the negative side, the Fear & Greed Index at 31 (extreme fear) detracts -1.07%, the 504-day chart pattern reduces probability by -0.86%, and high beta (2.59, top 10%) and maximum volatility (13.77, top 10%) each weigh down by -0.74% and -0.69%, respectively. Notable data points include operating cash flow in the bottom 10% (negative $30.8M), which surprisingly contributes positively, while high beta and volatility in the top 10% act as detractors. Tangible shareholders' equity ($179.7M) ranks in the top 50% and adds +0.39%, and institutional ownership at 60.87% (top 50%) adds +0.28%. Overall, the stock shows a mixed picture: positive industry and fundamental tailwinds are offset by high volatility and bearish sentiment, resulting in a modest edge over the market and a neutral HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+2.46%
How the stock is priced relative to its fundamentals
Sentiment+0.83%
How analysts and the market view the stock
Earnings Quality+0.79%
Stability and reliability of reported earnings
Size & Liquidity+0.27%
Company size and trading liquidity
Momentum+0.07%
Direction and strength of recent price movements

Volatility-1.58%
How much the stock price tends to fluctuate
Profitability-0.26%
Profitability and operating efficiency metrics

FATE probability advantage of beating the market (3M):

+2.57%

AI Score

Hold

Fate Therapeutics (FATE) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +2.57% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of FATE (53.39%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
FATE probability advantage of beating the market (3M)+2.57%
FATE probability of beating the market (3M)53.39%

FATE probability advantage of beating the market (3M): +2.57%

The AI-powered overall analysis of Fate Therapeutics (FATE) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of FATE:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.38%
Sentiment	Industry (GICS)	Biotechnology	N/A	+1.31%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.07%
Technical	Chart Pattern (504d)	figure_13	N/A	-0.86%
Fundamental	Operating Cash Flow (Qtr Discrete)	-30.82	N/A	+0.79%
Technical	Beta	2.59		-0.74%
Technical	Maximum Volatility	13.77%		-0.69%
Fundamental	Tangible Shareholders' Equity	179.71		+0.39%
Technical	Chart Pattern (60d)	figure_55	N/A	+0.37%
Technical	Alpha Last Day	0.13%		-0.32%
Technical	Upgrade to unlock			+0.31%
Technical	Upgrade to unlock			+0.31%
Fundamental	Upgrade to unlock			-0.31%
Sentiment	Upgrade to unlock			+0.28%
Technical	Upgrade to unlock			-0.28%

Rest of Alpha Signals: +0.69%

FATE probability advantage of beating the market (3M)Total:+2.57%
FATE AI Score

Significant changes Vs previous day

FATE Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$3.04
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

FATE Proven Hold Signal & Price Forecast

This is the price chart for FATE from January 1, 2026 until today. The chart indicates, in yellow, the 55 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

FATE Average Past Performance & Win Rate

Three months after its 1361 Hold signals since July 2026, FATE had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1361 Past FATE Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+40.07%
Average Alpha				+27.59%
Win Rate (% Positive Perf.)				50.09%
% Positive Alpha				43.43%

FATE Frequently Asked Questions

Will Fate Therapeutics stock go up?
According to Danelfin AI, Fate Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Fate Therapeutics stock?
Is it a good time to buy, sell, or hold Fate Therapeutics stock right now?
Is Fate Therapeutics undervalued right now?
What was the price range of Fate Therapeutics stock over the past 12 months?
What is going on with Fate Therapeutics stock in the last 3 months?
Does Fate Therapeutics offer dividend payments?
What is the current market capitalization of Fate Therapeutics?
When is the next FATE earnings report date?

Fate Therapeutics Inc Company Profile

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on architecting advanced cellular immunotherapies for both cancer and immune disorders worldwide. Segmented into two primary areas of research—chimeric antigen receptor (CAR)-targeted NK and T-cell products—the company is actively developing candidates such as the FT576 for tackling multiple myeloma, and FT522 as a formidable response to lymphoma and various autoimmune disorders.

Further advancements are reflected in their CAR T-cell initiatives. FT819, another product under development, is aimed towards addressing hematologic malignancies and solid tumors, while FT825 bears potential in treating solid tumors specifically.

Adding to its expansive portfolio, Fate Therapeutics also enlists collaborative partnerships as a part of its strategic growth plan. Notably, it has entered into an agreement with Ono Pharmaceutical Co. Ltd focusing on the development and commercialization of ready-to-use iPSC-derived CAR T-cell therapeutic candidates to strengthen its ongoing fight against cancer.

The genesis of Fate Therapeutics, Inc traces back to 2007 when it was incorporated in San Diego, California – where it continues to be based – steering advanced solutions to revolutionize healthcare care on a global level.

Sector:
Country:United States
Industry:
Address:12278 Scripps Summit Drive, San Diego
Employees:161
Website:fatetherapeutics.com

Pros

Proprietary induced pluripotent stem cell platform

Off-the-shelf allogeneic cell therapy potential

Broad therapeutic applicability of iPSC technology

Reduced manufacturing variability for cell products

Extensive intellectual property protection for cell engineering

Cons

Elevated research and development capital intensity

High clinical trial failure rates for novel therapies

Complex regulatory approval pathways for cell therapies

Intense competition in allogeneic cell therapy development

Manufacturing scalability challenges for biological products

FATE Stock AI Analysis